Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 1/20 | 0.36 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.35 |
| ▸ | HTR2A | P28223 | 1/20 | 0.35 |
| ▸ | HTR2C | P28335 | 1/20 | 0.35 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.35 |
| ▸ | HTR7 | P34969 | 1/20 | 0.35 |
| ▸ | HTR2B | P41595 | 1/20 | 0.35 |
| ▸ | HTR3A | P46098 | 1/20 | 0.35 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.35 |
| ▸ | HTR4 | Q13639 | 1/20 | 0.35 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.33 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.33 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.33 |
| ▸ | HRH1 | P35367 | 2/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL4432885 | 0.98 | EPHX2 (0.35) | EPHX2SLC6A2HTR2AHTR2CSLC6A4 | |
| SCHEMBL10290697 | 0.87 | — | — | |
| SCHEMBL24764448 | 0.87 | — | — | |
| Trifluoroacetic Acid SCHEMBL27730437 | 0.83 | EPHX2 (0.36) | EPHX2SLC6A2SLC6A4HRH1 | |
| SCHEMBL3933914 | 0.83 | — | — | |
| SCHEMBL472084 | 0.83 | EPHX2 (0.44) | EPHX2ALDH1A1 | |
| SCHEMBL3943544 | 0.78 | — | — | |
| SCHEMBL3945815 | 0.78 | — | — | |
| SCHEMBL49322 | 0.76 | NPC1 (0.40) | EPHX2ALDH1A1 | |
| SCHEMBL4570339 | 0.76 | EPHX2 (0.41) | EPHX2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102417502-B | Azole antifungal compound, salts, preparation method and application thereof | UNIV PLA 2ND MILITARY MEDICAL | 2014-05-28 | — | — | CN | claimed |
| CN-102417502-A | Azole antifungal compound, salts, preparation method and application thereof | UNIV PLA 2ND MILITARY MEDICAL | 2012-04-18 | — | — | CN | claimed |
| WO-2005030704-A1 | INHIBITORS OF HISTONE DEACETYLASE | METHYLGENE, INC. (CA) | 2005-04-07 | — | — | WO | claimed |
| EP-4688779-A2 | NOVEL COMPOUNDS AND USES THEREOF | Acelink Therapeutics, Inc. (US) | 2026-02-11 | — | — | EP | disclosed |
| WO-2024211244-A2 | NOVEL COMPOUNDS AND USES THEREOF | ACELINK THERAPEUTICS, INC. (US) | 2024-10-10 | — | — | WO | disclosed |
| US-9522906-B2 | Tetrahydroquinoline analogues as muscarinic agonists | ACADIA PHARMACEUTICALS, INC. (US) | 2016-12-20 | — | — | US | disclosed |
| CN-102796095-B | As the tetrahydroquinoline analogues of muscarinic agonist | ACADIA PHARMACEUTICAL, INC. (US) | 2015-09-09 | — | — | CN | disclosed |
| US-20140221364-A1 | TETRAHYDROQUINOLINE ANALOGUES AS MUSCARINIC AGONISTS | ACADIA PHARMACEUTICALS, INC. (US) | 2014-08-07 | — | — | US | disclosed |
| CN-102417502-B | Azole antifungal compound, salts, preparation method and application thereof | UNIV PLA 2ND MILITARY MEDICAL | 2014-05-28 | — | — | CN | disclosed |
| US-8680115-B2 | Tetrahydroquinoline analogues as muscarinic agonists | ACADIA PHARMACEUTICALS, INC. (US) | 2014-03-25 | — | — | US | disclosed |
| CN-102796095-A | Tetrahydroquinoline analogues as muscarinic agonists | ACADIA PHARM INC | 2012-11-28 | — | — | CN | disclosed |
| EP-1264858-B1 | POLYACETAL RESIN COMPOSITION AND PROCESS FOR ITS PRODUCTION | POLYPLASTICS CO (JP) | 2006-07-26 | — | — | EP | disclosed |
| WO-2006068904-A1 | TETRAHYDROQUINOLINE ANALOGUES AS MUSCARINIC AGONISTS | ACADIA PHARMACEUTICALS INC. (US) | 2006-06-29 | — | — | WO | disclosed |
| EP-1461318-B9 | TETRAHYDROQUINOLINE ANALOGUES AS MUSCARINIC AGONISTS | ACADIA PHARM INC (US) | 2005-12-28 | — | — | EP | disclosed |
| US-20050209226-A1 | Neurodegenerative diseases, psychological disorders; e.g. 4-[3-(3a -Cyclopropylmethoxy-8-azabicyclo[3.2.1]oct-8-yl)-2-methylpropyl]-4H-benzo[1.4]oxazin-3-one | ACADIA PHARMACEUTICALS INC. | 2005-09-22 | — | — | US | disclosed |
| EP-1461318-B1 | TETRAHYDROQUINOLINE ANALOGUES AS MUSCARINIC AGONISTS | ACADIA PHARM INC (US) | 2005-09-14 | — | — | EP | disclosed |
| CN-1635891-A | Tetrahydroquinoline analogues as muscarinic agonists | ACADIA PHARM INC (US) | 2005-07-06 | — | — | CN | disclosed |
| EP-1461318-A2 | TETRAHYDROQUINOLINE ANALOGUES AS MUSCARINIC AGONISTS | Acadia Pharmaceuticals Inc. (US) | 2004-09-29 | — | — | EP | disclosed |
| US-20030176418-A1 | Tetrahydroquinoline analogues as muscarinic agonists | ACADIA PHARMACEUTICALS INC. | 2003-09-18 | — | — | US | disclosed |
| WO-2003057672-A2 | TETRAHYDROQUINOLINE ANALOGUES AS MUSCARINIC AGONISTS | ACADIA PHARMACEUTICALS, INC. (US) | 2003-07-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050209226-A1 | Neurodegenerative diseases, psychological disorders; e.g. 4-[3-(3a -Cyclopropylmethoxy-8-azabicyclo[3.2.1]oct-8-yl)-2-methylpropyl]-4H-benzo[1.4]oxazin-3-one | CHRNA4, CHRNA2, CHRNA5 | EPHX2 2152/4885SLC6A2 341/4885HTR2A 30/4885 |
| US-20030176418-A1 | Tetrahydroquinoline analogues as muscarinic agonists | CHRM3, CHRM5, CHRM2 | EPHX2 667/4885SLC6A2 750/4885HTR2A 194/4885 |
| US-20140221364-A1 | TETRAHYDROQUINOLINE ANALOGUES AS MUSCARINIC AGONISTS | CHRM3, CHRM5, CHRM2 | EPHX2 667/4885SLC6A2 750/4885HTR2A 194/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.